Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

118 results about "Receptor potential" patented technology

A receptor potential, also known as a generator potential, a type of graded potential, is the transmembrane potential difference produced by activation of a sensory receptor. A receptor potential is often produced by sensory transduction. It is generally a depolarizing event resulting from inward current flow. The influx of current will often bring the membrane potential of the sensory receptor towards the threshold for triggering an action potential. Receptor potential can work to trigger an action potential either within the same neuron or on an adjacent cell. Within the same neuron, a receptor potential can cause local current to flow to a region capable of generating an action potential by opening voltage gated ion channels. A receptor potential can also cause the release of neurotransmitters from one cell that will act on another cell, generating an action potential in the second cell. The magnitude of the receptor potential determines the frequency with which action potentials are generated, and is controlled by adaption, stimulus strength, and temporal summation of successive receptor potentials. Receptor potential relies on receptor sensitivity which can adapt slowly, resulting in a slowly decaying receptor potential or rapidly, resulting in a quickly generated but shorter lasting receptor potential.

Compositions and methods for transient receptor potential vanilloid (TRPV) channel mediated treatments

InactiveUS20080051454A1Increasing TRPV1-responsesCompound screeningBiocideScreening methodArachidonic acid supplementation
The present inventions relate to therapeutic compositions comprising, and methods utilizing, arachidonic acid derivatives and analogs for treatment of patients demonstrating symptoms of pathological conditions. Specifically, the inventions relate to therapeutic compositions for activating transient receptor potential vanilloid-1 channels (TRPV1). Additionally, therapeutic compositions are provided for increasing TRPV1-type responses. These pathological conditions include, but are limited to, hypertension, in particular salt induced hypertension, and cardiovascular complications, including myocardial infarction, kidney dysfunction, diabetes, and inflammation. Further, the inventions relate to drug screening methods for providing additional therapeutic compounds.
Owner:MICHIGAN STATE UNIV

Radioligands for the TRP-M8 receptor and methods therewith

One embodiment of the invention is a composition that comprises a radioactive [18F], [123I], [125I], or [131I]—N-radiohaloaryl-alkylcarboxamide molecule. The composition binds to the transient receptor potential-M8 (TRP-M8) receptor of cells. The TRP-M8 receptor is selectively expressed in sensory neurons and in malignant tissues such as prostate cancer cells. The [18F], [123I], [125I], or [131I]—N-radiohaloaryl-alkylcarboxamide ligand may be used for radioreceptor binding studies, for diagnostic studies, and for radiotherapy of cancerous tissues. Affinity of the [125I] or [131I]—N-radiohaloaryl-alkylcarboxamide ligand for the TRP-M8 receptor confers selectivity and specificity in delivering lethal radiation to the diseased cells.
Owner:WEI EDWARD T

2-amino-4-arylthiazole compounds as trpai antagonists

The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and / or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and / or disorders modulated by TRPA1.
Owner:GLENMARK PHARMA SA

New application of 6-gingerol

The invention discloses new application of 6-gingerol. The 6-gingerol is used for respectively regulating M8 and V1 subtype transient receptor potential ion channels (short for TRPM8 and TRPV1) of mammals including humans and can be also used for preparing medicaments for treating related diseases, such as cryalgesia allergy, the parkinsonism, painful bladder syndrome, chronic obstructive pulmonary diseases, and the like as well as tumors of skin, the prostate gland, the mammary gland, the lung, the colon, and the like, participated by the ion channels. The action intensity of the 6-gingerol is higher than that of capsaicin.
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI

TRPC6 involved in glomerulonephritis

InactiveUS20060257500A1Calcium ion influx is thereby reducedCompound screeningBiocideEtiologyDisease
Focal and segmental glomerulosclerosis (FSGS) is a kidney disorder of unknown etiology and up to 20% of patients on dialysis have this diagnosis. A large family with hereditary FSGS carries a missense mutation in the TRPC6 gene on chromosome 11q, encoding the ion channel protein Transient Receptor Potential Cation Channel 6. The missense mutation is a P112Q substitution, which occurs in a highly conserved region of the protein, enhances TRPC6-mediated calcium signals in response to agonists such as angiotensin II, and alters the intracellular distribution of TRPC6 protein. Previous work has emphasized the importance of cytoskeletal and structural proteins in proteinuric kidney diseases. Our findings suggest a novel mechanism for glomerular disease pathogenesis.
Owner:DUKE UNIV

Target spot and medicine for treating cerebral injury

The invention relates to a target spot and a medicine for treating cerebral injury, in particular to a material used for maintaining TRPC6 (Transient Receptor Potential-canonical Channel) level to prevent or treat hypoxic ischemic cerebral injury or cranial nerve retinal neurodegeneration, and application thereof in preparation of a medicine or medicine composition for preventing or treating the hypoxic ischemic cerebral injury or cranial nerve retinal neurodegeneration. The invention also relates to a method for screening materials capable of being used for treating or preventing injury caused by ischemia.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI

Trp inhibitors and uses thereof

InactiveUS20120148604A1BiocideNervous disorderTransient receptor potential channelTRPC4
The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.
Owner:POSEIDA THERAPEUTICS INC

Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons

InactiveUS20060142547A1Reducing nociceptive painReduce painNervous disorderBacteriaThermoreceptorMammal
The methods and compositions of the invention are based on a method for measuring nociceptive responses in vertebrates, including humans and other mammals utilizing a newly discovered thermoreceptor belonging to the Transient Receptor Potential (TRP) family of non-selective cation channels that participates in thermosensation and pain. This receptor, designated ANKTMI, is associated with nociceptive pain, such as hyperalgesia. Accordingly, the invention provides isolated polypeptides and polynucleotides associated with nociception as well as methods for identifying or screening agents that modulate nociception.
Owner:NOVARTIS AG +1

New use of methyl liensinine

The invention discloses a new use of methyl liensinine. Methyl liensinine respectively regulates M8 and V1 subtype transient receptor potential ion channels (TRPM8 and TRPV1 for short) of mammal including human, so as to prepare medicine for treating related diseases joined by the ion channels (such as cold hyperalgesia, parkinsonism, nociceptive bladder syndrome, chronic obstructive lung diseaseand tumours of skin, prostate, breast, lung and colon). The action strength of methyl liensinine of the invention is higher than that of menthol.
Owner:INST OF CHINESE MATERIA MEDICA CHINA ACAD OF CHINESE MEDICAL SCI

Lung cancer tissue protein blotting membrane and preparation method thereof

The invention relates to a lung cancer tissue protein blotting membrane and a preparation method thereof. The membrane is prepared by the extraction of lung cancer tissue protein, electrophoretic separation and membrane conversion. The preparation method is characterized in that a polyvinylidene fluoride (PVDF) membrane is contained, and an instantaneous receptor potential channel TAPC6 is formed on the PVDF membrane, wherein the molecular weight is between 120kda and 85kda of the non-prestained protein molecular weight standard; or a cytoskeletal protein immune blot is formed on the activated PVDF membrane, wherein the cytoskeletal protein is above 40kda of the non-prestained protein molecular weight standard. The invention has convenient and quick storage and transportation and can be repetitively used, therefore the lung cancer specimen resource and the research are integrated and utilized efficiently; the researcher can obtain the relevant data when the subsequent immune reaction is completed after the lung cancer immune blotting, thereby saving the time of scientific research and enhancing the efficiency.
Owner:广州医学院 +1

Substituted pyrrole-4-alkylamine compounds and application thereof

The invention relates to substituted pyrrole-4-alkylamine compounds and application thereof. The invention particularly provides application of compounds shown in a formula I, or optical isomers thereof, or racemates thereof, or solvates thereof, or pharmaceutically acceptable salts thereof; the compounds as well as the optical isomers, the racemates, the solvates and the pharmaceutically acceptable salts thereof are used for preparing pharmaceutical compositions or preparations; the pharmaceutical compositions or preparations are used for (a) inhibiting a transient receptor potential channelprotein, and (b) treating diseases related to the transient receptor potential channel protein; in the formula, the definition of all groups is shown in the description. The formula I is shown in thedescription.
Owner:SHANGHAI LEADO PHARMATECH CO LTD

TRPV1 (transient receptor potential cation channel, subfamily V, member 1) antagonists, and preparation method and medical application thereof

ActiveCN102304104AUrea derivatives preparationAntipyreticTransient receptor potential channelSensory potential
The invention relates to compounds shown as a general formula (1) and salts of the compounds. The compounds are TRPV1 (transient receptor potential cation channel, subfamily V, member 1) antagonists, and have better analgesic action. The invention also relates to a preparation method for the compounds, medicinal preparations containing the compounds, and application of the compounds and medicinal compositions thereof in treatment of pain.
Owner:CHINA PHARM UNIV

Application of dragon's blood and flavonoid chemical component thereof in serving as antagonist of capsaicin receptor TRPV1 (transient receptor potential vanilloid 1)

InactiveCN102406787AStrong activation inhibitionEnhance pharmacological effectsNervous disorderAntipyreticDiseaseCochinchinenin
The invention relates to applications of dragon's blood and a flavonoid chemical component thereof in serving as an antagonist of a capsaicin receptor TRPV1 (transient receptor potential vanilloid 1) and in preparing a medicament for treating diseases related to TRPV1 receptors, wherein the flavonoid chemical component is cochinchinenin A or a mixture of at least two of cochinchinenin A, cochinchinenin B and loureirin B. The invention also relates to a medicinal composition comprising the dragon's blood and and the flavonoid chemical component thereof. Independent component of the dragon's blood or the cochinchinenin A, or a combination of every two of the cochinchinenin A, the cochinchinenin B and the loureirin B, or a combination comprising the cochinchinenin A, the cochinchinenin B and the loureirin B has strong capsaicin receptor TRPV1 activation inhibition effect and excellent pharmacological action based on the inhibition effect, so that the dragon's blood or the flavonoid chemical component thereof serving as an active component can be used for preparing medicaments for treating or preventing TRPV1 related diseases, such as nociceptive pains, neurogenic pains, cancer pains, headache, urinary bladder functional disorder, inflammation and the like.
Owner:SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES

Agent for inducing receptor potential

Disclosed is an agent for inducing receptor potential, which comprises an organic dye compound capable of inducing / evoking receptor potential in response to photostimulation in the optic nerve, wherein the organic dye compound is a polymethine organic dye compound. Also disclosed is a substituent material for the retina comprising the agent.
Owner:UNIV OKAYAMA

Novel heterocyclidene acetamide derivative

Disclosed are a compound represented by the formula (I') below, a salt thereof, and a solvate of any of them. Also disclosed are a pharmaceutical composition containing such a compound as an active ingredient, and a TRPV 1 (Transient Receptor Potential Type I) receptor antagonist. [Chemical formula 1] (I') (In the formula, m, n and p respectively represent 0-2; q represents 0-1; R1 represents ahalogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO2 group or the like; R2 represents a halogen, an amino, a hydrocarbon group, an aromatic heterocyclic group or an oxo group; X1 represents O, -NR3- or -S(O)r-; X2 represents a methylene group, O, -NR3- or -S(O)r-; Q' represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group or aralkyl group; the cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-form or a Z-form.).
Owner:MOCHIDA PHARM CO LTD

Compound for inhibiting trpv3 function and use thereof

The present invention relates to a TRPV3 (transient receptor potential vanilloid 3) activity inhibitor, more precisely to a method for inhibiting TRPV3 activity including the step of treating isopentenyl pyrophosphate and a method for treating skin disease containing the step of administering isopentenyl pyrophosphate to a subject with skin disease or applying the same on the skin of the subject. Isopentenyl pyrophosphate of the present invention controls increase of sensory cell reactivity to current or migration and proliferation of skin cells induced by TRPV3, so that it can be effectively used for the development of a pain reliever or a therapeutic agent for skin disease.
Owner:KOREA UNIV IND & ACADEMIC CALLABORATION FOUND

2-amino-4-arylthiazole compounds as TRPA1 antagonists

The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and / or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and / or disorders modulated by TRPA1.
Owner:GLENMARK PHARMA SA

Bioavailability enhancing compound

For enhancing bioavailability, a composition is administered comprising a Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) agonist with a combined Scoville Heat Unit (SHU) milligram (mg) dose in the range of 280,000 to 400,000 SHU mg.
Owner:WARNOCK W MATTHEW

Compound containing farnesyl diphosphate for modulating trpv3 function and use thereof

The present invention relates to a method for activating TRPV3 (transient receptor potential vanilloid 3) using FPP (farnesyl diphosphate) and a method for screening a TRPV3 activity inhibitor. FPP of the present invention has TRPV3 specific activity and therefore it can be effectively used for the study on TRPV3 mechanism and functions and for the development of a TRPV3 based pain reliever.
Owner:KOREA UNIV IND & ACADEMIC CALLABORATION FOUND

Antagonists of the transient receptor potential vanilloid 1 and uses thereof

One of the major disabling symptoms of gastroparesis is nausea and vomiting which can be difficult to control with currently available treatments. It is postulated that signaling of gastrointestinal causes of nausea starts with activation of vagal afferent nerves that trigger the central emetic pathway. Most vagal afferent nerves are unmyelinated C-fibers, many of which express the vanilloid receptor TRPV1 and respond to capsaicin. Resiniferatoxin is a very potent capsaicin analogue that has a much more favorable ratio of desensitization to excitation than capsaicin leading to more effective desensitization without irritation. The present invention demonstrates that desensitization of TRPV1 responsive gastric sensory neurons would attenuate nausea and vomiting.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

1,2,3,4-tetrahydro-9H-pyridino[3,4-b]indole transient receptor potential vanilloid 1 (TRPV1) antagonist and application thereof

The invention relates to a 1,2,3,4-tetrahydro-9H-pyridino[3,4-b]indole transient receptor potential vanilloid 1 (TRPV1) antagonist or a pharmaceutically-acceptable salt thereof. The structure generalformula is shown in the specifications, in the formula, R is H, or F, or Cl, or Br, or I, or CF3, or methyl, or isopropyl, or tertiary butyl, or cyclopropyl, or propenyl, or acetenyl, or hydroxyl, orphenoxyl, or acetyl or phenyl; n is 1, or 2 or 3; L is triazole, or tetrazole, or carbamido or thioureido; Ar is phenyl, or pyridyl, or isoquinolyl, or quinolyl or pyrimidyl. Through tests, it is found that 1,2,3,4-tetrahydro-9H-pyridino[3,4-b]indole compounds have good TRPV1 inhibitory activity, and the activity of part of the compounds is far higher than that of a TRPV1 receptor antagonist BCTC;compared with the BCTC, the side effect of body temperature increasing is almost avoided. Therefore, the 1,2,3,4-tetrahydro-9H-pyridino[3,4-b]indole compounds as shown in the general formula and medicinal salts thereof are safe and effective and have a high analgesic effect.
Owner:HENAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products